Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC. Luiten RM, et al. Among authors: sein j. J Clin Oncol. 2005 Dec 10;23(35):8978-91. doi: 10.1200/JCO.2005.01.6816. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260696 Clinical Trial.
Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH. de Gast GC, et al. Among authors: sein j. Clin Cancer Res. 2000 Apr;6(4):1267-72. Clin Cancer Res. 2000. PMID: 10778950 Clinical Trial.
Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer.
de Gast GC, Vyth-Dreese FA, Nooijen W, van den Bogaard CJ, Sein J, Holtkamp MM, Linthorst GA, Baars JW, Schornagel JH, Rodenhuis S. de Gast GC, et al. Among authors: sein j. J Clin Oncol. 2002 Jan 1;20(1):58-64. doi: 10.1200/JCO.2002.20.1.58. J Clin Oncol. 2002. PMID: 11773154 Clinical Trial.
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC. Verra N, et al. Among authors: sein j. Br J Cancer. 2003 May 6;88(9):1346-51. doi: 10.1038/sj.bjc.6600915. Br J Cancer. 2003. PMID: 12778059 Free PMC article. Clinical Trial.
Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma.
Vyth-Dreese FA, Sein J, van de Kasteele W, Dellemijn TA, van den Bogaard C, Nooijen WJ, de Gast GC, Haanen JB, Bex A. Vyth-Dreese FA, et al. Among authors: sein j. Clin Exp Immunol. 2010 Dec;162(3):447-59. doi: 10.1111/j.1365-2249.2010.04274.x. Epub 2010 Oct 5. Clin Exp Immunol. 2010. PMID: 20942806 Free PMC article.
Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.
Vlasveld LT, Hekman A, Vyth-Dreese FA, Melief CJ, Sein JJ, Voordouw AC, Dellemijn TA, Rankin EM. Vlasveld LT, et al. Among authors: sein jj. Cancer Immunol Immunother. 1995 Jan;40(1):37-47. doi: 10.1007/BF01517234. Cancer Immunol Immunother. 1995. PMID: 7530170 Free PMC article. Clinical Trial.
67 results